Phase 3 Readout
RLAY: Phase 3 Topline: Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Wit
December 31, 2026 · fulvestrant. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 31, 2026
- Company
- Relay Therapeutics, Inc. (RLAY)
- Drug
- fulvestrant
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Wit
- Drug
- fulvestrant
- Indication
- Breast Cancer